ES2828435T3 - Compuesto derivado de pirazolina y su uso en una pauta posológica semanal contra la inflamación y el dolor derivados de la enfermedad articular degenerativa en mamíferos - Google Patents
Compuesto derivado de pirazolina y su uso en una pauta posológica semanal contra la inflamación y el dolor derivados de la enfermedad articular degenerativa en mamíferos Download PDFInfo
- Publication number
- ES2828435T3 ES2828435T3 ES15778958T ES15778958T ES2828435T3 ES 2828435 T3 ES2828435 T3 ES 2828435T3 ES 15778958 T ES15778958 T ES 15778958T ES 15778958 T ES15778958 T ES 15778958T ES 2828435 T3 ES2828435 T3 ES 2828435T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- body weight
- dose
- loading dose
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 74
- 230000003442 weekly effect Effects 0.000 title claims abstract description 64
- 208000002193 Pain Diseases 0.000 title claims abstract description 59
- 230000036407 pain Effects 0.000 title claims abstract description 50
- 150000001875 compounds Chemical class 0.000 title claims abstract description 48
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 41
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 33
- 241000124008 Mammalia Species 0.000 title description 15
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 title description 3
- 238000011282 treatment Methods 0.000 claims abstract description 141
- 230000037396 body weight Effects 0.000 claims abstract description 97
- 241000282472 Canis lupus familiaris Species 0.000 claims abstract description 59
- 238000012423 maintenance Methods 0.000 claims abstract description 49
- 208000030175 lameness Diseases 0.000 claims description 34
- 206010003246 arthritis Diseases 0.000 claims description 20
- 208000000094 Chronic Pain Diseases 0.000 claims description 8
- 208000037976 chronic inflammation Diseases 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 description 34
- 238000000034 method Methods 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 24
- 230000006698 induction Effects 0.000 description 24
- 229940079593 drug Drugs 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 12
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 230000000977 initiatory effect Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000011269 treatment regimen Methods 0.000 description 9
- 230000001760 anti-analgesic effect Effects 0.000 description 8
- 230000003412 degenerative effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000004722 stifle Anatomy 0.000 description 8
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 7
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 4
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 4
- 208000026816 acute arthritis Diseases 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 229940111134 coxibs Drugs 0.000 description 4
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000282465 Canis Species 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- KYXDNECMRLFQMZ-UHFFFAOYSA-N cimicoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=C(Cl)N=CN1C1=CC=C(S(N)(=O)=O)C=C1 KYXDNECMRLFQMZ-UHFFFAOYSA-N 0.000 description 3
- FULAPETWGIGNMT-UHFFFAOYSA-N firocoxib Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OCC1CC1 FULAPETWGIGNMT-UHFFFAOYSA-N 0.000 description 3
- TTZNQDOUNXBMJV-UHFFFAOYSA-N mavacoxib Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(F)=CC=2)=CC(C(F)(F)F)=N1 TTZNQDOUNXBMJV-UHFFFAOYSA-N 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- ZEXGDYFACFXQPF-UHFFFAOYSA-N robenacoxib Chemical compound OC(=O)CC1=CC(CC)=CC=C1NC1=C(F)C(F)=CC(F)=C1F ZEXGDYFACFXQPF-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 229940043081 onsior Drugs 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940106299 previcox Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000005065 subchondral bone plate Anatomy 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- XDKLKFULWJYRCB-UHFFFAOYSA-N 7,9-dihydro-3h-purine-2,6,8-trione;sodium Chemical compound [Na].N1C(=O)NC(=O)C2=C1NC(=O)N2 XDKLKFULWJYRCB-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950010851 cimicoxib Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- -1 fatty acid esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960002524 firocoxib Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229950007241 mavacoxib Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000205 robenacoxib Drugs 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382396.1A EP3009137A1 (en) | 2014-10-16 | 2014-10-16 | Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals |
| PCT/EP2015/073635 WO2016059028A1 (en) | 2014-10-16 | 2015-10-13 | Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2828435T3 true ES2828435T3 (es) | 2021-05-26 |
Family
ID=51844648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15778958T Active ES2828435T3 (es) | 2014-10-16 | 2015-10-13 | Compuesto derivado de pirazolina y su uso en una pauta posológica semanal contra la inflamación y el dolor derivados de la enfermedad articular degenerativa en mamíferos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11154536B2 (enExample) |
| EP (2) | EP3009137A1 (enExample) |
| JP (1) | JP6655625B2 (enExample) |
| CN (2) | CN115154465A (enExample) |
| AR (1) | AR102295A1 (enExample) |
| CA (1) | CA2964428C (enExample) |
| CY (1) | CY1123243T1 (enExample) |
| DK (1) | DK3206684T3 (enExample) |
| ES (1) | ES2828435T3 (enExample) |
| HR (1) | HRP20201233T1 (enExample) |
| HU (1) | HUE050511T2 (enExample) |
| LT (1) | LT3206684T (enExample) |
| MX (1) | MX376725B (enExample) |
| PL (1) | PL3206684T3 (enExample) |
| PT (1) | PT3206684T (enExample) |
| RS (1) | RS60777B1 (enExample) |
| SI (1) | SI3206684T1 (enExample) |
| SM (1) | SMT202000415T1 (enExample) |
| TW (1) | TWI707678B (enExample) |
| WO (1) | WO2016059028A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109303784B (zh) * | 2018-09-30 | 2020-06-23 | 山东省文登整骨医院 | 痛风性关节炎动物模型的构建方法 |
| TWI875757B (zh) * | 2019-05-08 | 2025-03-11 | 瑞士商諾華公司 | T1dm和胰島炎治療中使用之抗cd40抗體 |
| EP4029502A1 (en) | 2021-01-15 | 2022-07-20 | Ecuphar N.V. | Pyrazoline-derived compound (enflicoxib) for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals |
| US12208085B2 (en) | 2022-05-31 | 2025-01-28 | Ecuphar Nv | Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU773615B2 (en) * | 1997-05-05 | 2004-05-27 | Pfizer Inc. | COX-2 selective carprofen for treating pain and inflammation in dogs |
| ES2137138B1 (es) | 1998-05-29 | 2000-09-16 | Esteve Labor Dr | Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos. |
| US20050131028A1 (en) * | 2003-09-11 | 2005-06-16 | Pharmacia Corporation | Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders |
| CN101175769A (zh) * | 2005-03-10 | 2008-05-07 | 健泰科生物技术公司 | 用于调控血管完整性的方法和组合物 |
-
2014
- 2014-10-16 EP EP14382396.1A patent/EP3009137A1/en not_active Withdrawn
-
2015
- 2015-10-13 ES ES15778958T patent/ES2828435T3/es active Active
- 2015-10-13 CN CN202210698831.5A patent/CN115154465A/zh active Pending
- 2015-10-13 SM SM20200415T patent/SMT202000415T1/it unknown
- 2015-10-13 DK DK15778958.7T patent/DK3206684T3/da active
- 2015-10-13 CN CN201580068592.3A patent/CN107257684A/zh active Pending
- 2015-10-13 PT PT157789587T patent/PT3206684T/pt unknown
- 2015-10-13 RS RS20200943A patent/RS60777B1/sr unknown
- 2015-10-13 MX MX2017004899A patent/MX376725B/es active IP Right Grant
- 2015-10-13 US US15/518,871 patent/US11154536B2/en active Active
- 2015-10-13 PL PL15778958T patent/PL3206684T3/pl unknown
- 2015-10-13 SI SI201531302T patent/SI3206684T1/sl unknown
- 2015-10-13 HR HRP20201233TT patent/HRP20201233T1/hr unknown
- 2015-10-13 WO PCT/EP2015/073635 patent/WO2016059028A1/en not_active Ceased
- 2015-10-13 EP EP15778958.7A patent/EP3206684B1/en active Active
- 2015-10-13 CA CA2964428A patent/CA2964428C/en active Active
- 2015-10-13 HU HUE15778958A patent/HUE050511T2/hu unknown
- 2015-10-13 LT LTEP15778958.7T patent/LT3206684T/lt unknown
- 2015-10-13 JP JP2017539508A patent/JP6655625B2/ja active Active
- 2015-10-16 AR ARP150103353A patent/AR102295A1/es not_active Application Discontinuation
- 2015-10-16 TW TW104134072A patent/TWI707678B/zh active
-
2020
- 2020-08-03 CY CY20201100714T patent/CY1123243T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3206684T3 (da) | 2020-08-10 |
| HRP20201233T1 (hr) | 2020-11-13 |
| CN115154465A (zh) | 2022-10-11 |
| MX376725B (es) | 2025-03-07 |
| TWI707678B (zh) | 2020-10-21 |
| PL3206684T3 (pl) | 2021-01-11 |
| WO2016059028A1 (en) | 2016-04-21 |
| EP3206684A1 (en) | 2017-08-23 |
| AR102295A1 (es) | 2017-02-15 |
| HUE050511T2 (hu) | 2020-12-28 |
| CY1123243T1 (el) | 2021-10-29 |
| JP6655625B2 (ja) | 2020-02-26 |
| CN107257684A (zh) | 2017-10-17 |
| PT3206684T (pt) | 2020-08-24 |
| EP3009137A1 (en) | 2016-04-20 |
| TW201625239A (zh) | 2016-07-16 |
| CA2964428A1 (en) | 2016-04-21 |
| JP2017531042A (ja) | 2017-10-19 |
| LT3206684T (lt) | 2020-10-12 |
| CA2964428C (en) | 2022-01-04 |
| SI3206684T1 (sl) | 2020-11-30 |
| US20170231961A1 (en) | 2017-08-17 |
| US11154536B2 (en) | 2021-10-26 |
| EP3206684B1 (en) | 2020-06-17 |
| RS60777B1 (sr) | 2020-10-30 |
| MX2017004899A (es) | 2018-02-12 |
| SMT202000415T1 (it) | 2020-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2828435T3 (es) | Compuesto derivado de pirazolina y su uso en una pauta posológica semanal contra la inflamación y el dolor derivados de la enfermedad articular degenerativa en mamíferos | |
| ES2241063T3 (es) | Tratamiento de la osteoartritis mediante la administracion de poli-n-acetil-d-glucosamina. | |
| Song et al. | Advanced strategies of drug delivery via oral, topical, and parenteral administration routes: where do equine medications stand? | |
| ES2324978T3 (es) | Un nuevo uso para deferiprona. | |
| US7025965B1 (en) | Method of use and dosage composition of bluegreen algae extract for inflammation in animals | |
| ES2740958T3 (es) | Composiciones de liberación controlada y sus procedimientos de uso | |
| KR102419769B1 (ko) | 약물 조성물 | |
| ITMI20060983A1 (it) | Composizioni farmaceutiche veterinarie per il trattamento del dolore e dell'inifiamazione | |
| BRPI0902699A2 (pt) | método quìmico para esterilização sexual e eliminação da libido em mamìferos do sexo masculino | |
| US20200330436A1 (en) | Compositions and Methods for Treatment and Prevention of Pyrexia in Horses | |
| Rowland | Use of a deslorelin implant to control aggression in a male bearded dragon (Pogona vitticeps) | |
| ES2207550T3 (es) | Composicion que comprende un extracto de perna canaliculus, metilsulfonilmetano y glucosamina, y utilizacion de la misma. | |
| JP6100510B2 (ja) | 抗感冒剤 | |
| RU2461387C2 (ru) | Способ лечения диспепсии у телят | |
| BRPI0713094A2 (pt) | métodos de administração de droga | |
| Wood et al. | Suspected lidocaine toxicity and the use of metoclopramide and neostigmine to treat post‐operative small intestinal ileus in a donkey | |
| RU2292203C1 (ru) | Средство для лечения болезней суставов | |
| ES2517395T3 (es) | Combinación de un analgésico de acción central y un agente antiinflamatorio inhibidor selectivo de la ciclooxigenasa-2 para el tratamiento de la inflamación y el dolor en el sector veterinario | |
| Bunnell et al. | Case report: Treatment of joint supplement toxicity resulting in acidemia, hyperglycemia, electrolyte derangements, and multiple organ dysfunction | |
| ES2543364A1 (es) | Composición farmacéutica que comprende la combinación de un agente antiinflamatorio no esteroideo, un agente adyuvante y un analgésico antineurítico, con efecto antinociceptivo | |
| Riviere et al. | Beta Lactam Antibiotics | |
| RU2006114078A (ru) | Лекарственный препарат и способ лечения ревматических заболеваний | |
| BR102017027200A2 (pt) | Composição para prevenção da intoxicação de ruminantes por plantas que contêm fluoroacetato e usos | |
| BR102017027200B1 (pt) | Composição para prevenção da intoxicação de ruminantes por plantas que contêm fluoroacetato e usos | |
| UA22108U (en) | Method to grow neonatal calves |